3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 1/2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
11
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Urinary Bladder Neoplasms
1
Interventions
Sunitinib
145
Nivolumab
144
pembrolizumab
132
Sorafenib
84
Bevacizumab
77
Everolimus
74
cabozantinib
71
pazopanib
65
Axitinib
65
Ipilimumab
62
aldesleukin
52
Magnetic Resonance Spectroscopy
45
Cyclophosphamide
40
Interleukin-2
38
lenvatinib
37
Specimen Handling
36
Radiosurgery
36
Interferon-alpha
32
atezolizumab
30
temsirolimus
27
belzutifan
24
Gemcitabine
23
fludarabine phosphate
22
avelumab
22
Radiotherapy
19
Interferon alpha-2
19
Biopsy
18
fludarabine
17
durvalumab
17
Nephrectomy
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Electroporation
×
Genitourinary
×
Clear all
NCT02335827
2021-09-05
IRE
Fuda Cancer Hospital, Guangzhou
Phase NA
Completed
15 enrolled
NCT01967407
2014-11-19
IRENE
University of Magdeburg
Phase 1/2
Unknown
20 enrolled